Literature DB >> 10777161

Rifampicin-associated pseudomembranous colitis.

A Nakajima1, S Yajima, T Shirakura, T Ito, Y Kataoka, K Ueda, D Nagoshi, H Kanemoto, N Matsuhashi.   

Abstract

We report a case of pseudomembranous colitis that developed in a patient with liver cirrhosis during anti-tuberculosis therapy with rifampicin and isoniazid. The association between rifampicin and pseudomembranous colitis has been controversial; this report, however, supports the association. Colonoscopy performed 3 days after the onset of the pseudomembranous colitis revealed only reddish patches and a few aphthoid lesions, but 4 days later pseudomembranes were apparent. The pseudomembranous colitis was successfully controlled by discontinuation of the anti-tuberculosis agents, along with the administration of lactic acid bacteria, without vancomycin or metronidazole. Possible predisposing factors for the development of pseudomembranous colitis in this patient are also discussed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10777161     DOI: 10.1007/s005350050350

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  5 in total

1.  Development of pseudomembranous colitis four months after initiation of rifampicin.

Authors:  Jeong Moon Choi; Hyung Hun Kim; Seun Ja Park; Moo In Park; Won Moon
Journal:  Case Rep Gastroenterol       Date:  2011-01-14

2.  A case of pseudomembranous colitis associated with rifampin.

Authors:  Ji Young Park; Joon Seok Kim; Sun Jong Jeung; Myung Sook Kim; Seok Chan Kim
Journal:  Korean J Intern Med       Date:  2004-12       Impact factor: 2.884

3.  Emergence of Clostridium difficile infection in tuberculosis patients due to a highly rifampicin-resistant PCR ribotype 046 clone in Poland.

Authors:  P Obuch-Woszczatyński; G Dubiel; C Harmanus; E Kuijper; U Duda; D Wultańska; A van Belkum; H Pituch
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-02-27       Impact factor: 3.267

4.  Rifampin-induced Pseudomembranous Colitis with Rectosigmoid Sparing.

Authors:  Sun Young Yim; Ja Seol Koo; Ye Ji Kim; Sang Jung Park; Jin Nam Kim; Sung Woo Jung; Hyung Joon Yim; Sang Woo Lee; Jai Hyun Choi; Chang Duck Kim
Journal:  Clin Endosc       Date:  2011-12-31

5.  Incidence and Clinical Outcomes of Clostridium difficile Infection after Treatment with Tuberculosis Medication.

Authors:  Yu Mi Lee; Kyu Chan Huh; Soon Man Yoon; Byung Ik Jang; Jeong Eun Shin; Hoon Sup Koo; Yunho Jung; Sae Hee Kim; Hee Seok Moon; Seung Woo Lee
Journal:  Gut Liver       Date:  2016-03       Impact factor: 4.519

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.